CORAL GABLES, FL / ACCESSWIRE / December 11, 2018 / The Brightfield Group, a research firm, recently published a 2018 market overview and analysis on hemp-derived CBD.
The summary of their analysis states, "Between 2017 and 2018, the U.S. hemp-derived CBD market has nearly doubled in size, but the five-year growth projections for this market are now dramatically higher than they were a year ago. This is because the full legalization of hemp-derived CBD is now a real and likely prospect following Republican Mitch McConnell's recent proposal of the Hemp Farming Act of 2018 (Farm Bill). This legislation - likely to pass later this year - would clearly and unambiguously legalize hemp as well as its derivatives, extractsand cannabinoids, including hemp CBD."
As the Farm Bill decision gets closer, here are four cannabis stocks to watch this month.
Premier Health Group (PHGRF) (PHGI) has begun conducting discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation. The company is looking to establish a framework for entry into the cannabis arena and its latest developments may also highlight to focus on growth ahead.
The company announced this week that as a part of its growth strategy to cover the major verticals associated with primary care, it has signed a binding Letter of Intent to acquire a Vancouver, British Columbia based pharmacy. Premier Health Group (PHGRF) (PHGI) said that it expects the acquisition to close in or about Q1-19.
"We are excited for this opportunity to acquire our first pharmacy, and thereafter being able to prepare and deliver prescription and non-prescription pharmaceuticals and other health products to patients. In doing so, the pharmacist will play an integral role in our team-based patient centric model," said Dr. Essam Hamza, CEO of Premier Health Group.
Premier Health Group (PHGRF) (PHGI) subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and has plans to rapidly increase that number both domestically and internationally.
iAnthus Capital Holdings, Inc. (ITHUF) has been trading higher for four consecutive days since hitting lows of $3.34 on December 6. The company owns, operates, and partners with licensed cannabis operations throughout the United States
Just a few weeks ago iAnthus released its quarterly operating results. Assets increased to $137.3 million at September 30, 2018, up from $45.8 million at December 31, 2017, as a result of the acquisitions in Florida and New York as well as the continued build-out of cultivation facilities and dispensaries across the operating entitles.
The Company also recorded an increase in consolidated revenues of 101% quarter-over-quarter, increasing to $1,074,398 in Q3 from $533,545 in Q2.
"iAnthus continues to execute. The Company has expanded its footprint and added to its industry leading team while maintaining a prudent balance sheet throughout the process," said Hadley Ford, CEO ofiAnthus.
Isodiol International Inc. (ISOLF) (ISOL.CN) is focused on the development of CBD-based pharmaceuticals and CBD consumer products. BSPG Laboratories™, a subsidiary of Isodiol®, was recently registered with the United Kingdom's Medicines and Healthcare products Regulatory Agency for producing CBD as an active pharmaceutical ingredient for use in pharmaceutical applications for humans and animals.
The company recently announced the appointment of Mr. Trent Gray as channel manager of the Iso-Sport Golf Division. "To be able to effectively market the benefits of CBD performance products to golfers and develop meaningful relationships is something I'm definitely looking forward to," Gray said in a statement.
Isodiol CEO, Marcos Agramont stated, "We believe his unique skill set will provide added value to the division as we continue to seek new opportunities while growing our footprint within various sports markets."
Shares of Isodiol were up sharply during Tuesday's morning session
Shares of Cara Tharapeutics (CARA) also jumped on Tuesday. The company has most recently been on the road to present at numerous investor conferences through the month of November.
In its most recently filed quarterly statement, Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics said, "In the past few months, we made significant clinical and corporate advancements, including the expanded pivotal Phase 3 development of KORSUVA™ Injection for chronic kidney disease-associated pruritus, or CKD-aP. We also strengthened our balance sheet with the successful completion of our follow-on offering and made key additions to our executive management team and board...We expect 2019 to be a significant year for Cara, with anticipated readouts from both of our pivotal Phase 3 trials of KORSUVA™ Injection in dialysis patients with CKD-aP, and data from our ongoing Phase 2 trial of Oral KORSUVA™ in non-dialysis patients with CKD-aP. We also expect to initiate our clinical development program of Oral KORSUVA™ in dermatological conditions."
Shares of Cara traded as high as $16.39 on Tuesday, up from $15.83 at Monday's close.
MarijuanaStocks.com is the leading web destination for all things cannabis. Investors can find marijuana-related financial, medical, legal, and social news anytime day or night. Writers are invited to submit cannabis related articles for publication.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. MAPH Enterprises LLC which owns www.MarijuanaStocks.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. MAPH Enterprises LLC, which owns www.MarijuanaStocks.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC (owners of MarijuanaStocks.com), MIDAM VENTURES, LLC and Premier Health Group Inc., Midam was hired for a period from 10/1/2018 - 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. Midam was paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six-month restriction is complete on 4/1/2019 Midam plans to sell the "500,000" shares of Premier Health Group Inc. that Midam holds currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for our full disclaimer.